NO20032758D0 - Krystallinske former av Atorvastatin - Google Patents

Krystallinske former av Atorvastatin

Info

Publication number
NO20032758D0
NO20032758D0 NO20032758A NO20032758A NO20032758D0 NO 20032758 D0 NO20032758 D0 NO 20032758D0 NO 20032758 A NO20032758 A NO 20032758A NO 20032758 A NO20032758 A NO 20032758A NO 20032758 D0 NO20032758 D0 NO 20032758D0
Authority
NO
Norway
Prior art keywords
crystalline forms
atorvastatin
directed
present
forms
Prior art date
Application number
NO20032758A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032758L (no
Inventor
Paul Adriaan Van Der Schaaf
Fritz Blatter
Martin Szelagiewicz
Kai-Uwe Schoening
Original Assignee
Ciba Sc Holding Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Sc Holding Ag filed Critical Ciba Sc Holding Ag
Publication of NO20032758L publication Critical patent/NO20032758L/no
Publication of NO20032758D0 publication Critical patent/NO20032758D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20032758A 2000-12-27 2003-06-17 Krystallinske former av Atorvastatin NO20032758D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00811249 2000-12-27
PCT/EP2001/015012 WO2002051804A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin

Publications (2)

Publication Number Publication Date
NO20032758L NO20032758L (no) 2003-06-17
NO20032758D0 true NO20032758D0 (no) 2003-06-17

Family

ID=8175112

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032758A NO20032758D0 (no) 2000-12-27 2003-06-17 Krystallinske former av Atorvastatin

Country Status (23)

Country Link
US (4) US7538136B2 (sk)
EP (2) EP2000461A1 (sk)
JP (2) JP2004516311A (sk)
KR (1) KR100790766B1 (sk)
CN (1) CN1273449C (sk)
AT (1) ATE420070T1 (sk)
AU (1) AU2002224952B2 (sk)
CA (7) CA2626317A1 (sk)
CZ (1) CZ20032019A3 (sk)
DE (1) DE60137364D1 (sk)
ES (1) ES2319870T3 (sk)
HR (1) HRP20030607A2 (sk)
HU (1) HUP0302519A3 (sk)
IL (1) IL156280A0 (sk)
IS (1) IS6859A (sk)
MX (1) MXPA03005879A (sk)
NO (1) NO20032758D0 (sk)
NZ (1) NZ527048A (sk)
PL (1) PL365312A1 (sk)
PT (1) PT1345896E (sk)
SK (1) SK9532003A3 (sk)
WO (1) WO2002051804A1 (sk)
ZA (1) ZA200304297B (sk)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
CA2426632C (en) * 2000-11-03 2008-08-05 Teva Pharmaceutical Industries, Ltd. Atorvastatin hemi-calcium form vii
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
MXPA03005879A (es) * 2000-12-27 2003-09-10 Ciba Sc Holding Ag Formas cristalinas de atorvastatina.
CA2450111C (en) * 2001-06-29 2006-02-07 Warner-Lambert Company Llc Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
US7074818B2 (en) 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
WO2003011826A1 (en) * 2001-07-30 2003-02-13 Dr. Reddy's Laboratories Ltd. Crystalline forms vi and vii of atorvastatin calcium
CN100430405C (zh) * 2001-08-16 2008-11-05 特瓦制药工业有限公司 制备他汀类的钙盐形式的方法
EP1572638A4 (en) * 2001-08-31 2010-05-05 Morepen Lab Ltd IMPROVED PROCESS FOR THE PREPARATION OF AMORPHOUS CALCIUM ATORVASTATIN SALT (2: 1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
ES2241507T1 (es) * 2002-02-15 2005-11-01 Teva Pharmaceutical Industries Ltd. Nuevas formas de cristal de atorvastatina semicalcica y procedimientos para su preparacion, asi como nuevos procedimientos para la preparacion de las formas i, viii y ix de atorvastatina semicalcica.
WO2003070665A2 (en) 2002-02-19 2003-08-28 Teva Pharmaceutical Industries Ltd. Desolvating solvates of atorvastatin hemi-calcium
JP2006503024A (ja) * 2002-09-03 2006-01-26 モレペン、ラボラトリーズ、リミテッド Ｖｉ型アトルバスタチンカルシウムまたはその水和物
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
AU2003297594A1 (en) * 2002-11-28 2004-06-23 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
EP1761489A1 (en) * 2004-03-17 2007-03-14 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
DK1727795T3 (da) 2004-03-17 2012-04-16 Ranbaxy Lab Ltd Fremgangsmåde til fremstillingen af atorvastatin-calcium i amorf form
CA2564030C (en) 2004-05-05 2010-06-08 Pfizer Products Inc. Salt forms of [r-(r*, r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
US8435530B2 (en) 2004-06-11 2013-05-07 Sbi Biotech Co., Ltd. Methods for suppressing activity of activated interferon-producing cells
CA2573969C (en) * 2004-07-16 2014-02-04 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2701710C (en) 2004-07-20 2013-08-27 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
RU2007115543A (ru) 2004-10-28 2008-12-10 Уорнер-Ламберт Компани Эл-Эл-Си (US) Способ получения аморфного аторвастатина
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
CA2499047A1 (en) * 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Process for producing atorvastatin hemicalcium
CZ2007772A3 (cs) * 2005-04-08 2008-02-27 EGIS GYOGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság Nová krystalická polymorfní forma hemivápenaté soli atorvastatinu
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
WO2007057755A1 (en) 2005-11-21 2007-05-24 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid magnesium
TW200745026A (en) * 2005-12-13 2007-12-16 Teva Pharma Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
KR20080031487A (ko) * 2006-06-28 2008-04-08 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴의 결정형
WO2009007856A2 (en) * 2007-07-11 2009-01-15 Actavis Group Ptc Ehf Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN104983702A (zh) * 2015-07-23 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
JP2019167295A (ja) * 2016-07-04 2019-10-03 ゼリア新薬工業株式会社 １，５−ベンゾジアゼピン化合物カルシウム塩の製造法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
ATE178794T1 (de) * 1993-01-19 1999-04-15 Warner Lambert Co Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
ATE284868T1 (de) * 1995-07-17 2005-01-15 Warner Lambert Co Kristaline (r-(r*,r*))-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- ((phenylamino)carbonyl)-1h-pyrrol-1- heptancarbonsäure hemi calcium sslz (atorvastatin)
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
PT1535613E (pt) * 1999-11-17 2010-10-04 Teva Pharma Processo de preparação de uma forma polimórfica de atorvastatina de cálcio
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
ATE320415T1 (de) * 1999-12-17 2006-04-15 Pfizer Science & Tech Ltd Verfahren zur herstellung von kristallin atorvastin kalcium
CA2426632C (en) 2000-11-03 2008-08-05 Teva Pharmaceutical Industries, Ltd. Atorvastatin hemi-calcium form vii
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
MXPA03005879A (es) * 2000-12-27 2003-09-10 Ciba Sc Holding Ag Formas cristalinas de atorvastatina.
WO2002057228A1 (en) 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
CA2450111C (en) * 2001-06-29 2006-02-07 Warner-Lambert Company Llc Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
WO2003011826A1 (en) * 2001-07-30 2003-02-13 Dr. Reddy's Laboratories Ltd. Crystalline forms vi and vii of atorvastatin calcium

Also Published As

Publication number Publication date
AU2002224952B2 (en) 2007-04-05
CA2623600A1 (en) 2002-07-04
US20060205805A1 (en) 2006-09-14
IS6859A (is) 2003-06-24
KR20030064880A (ko) 2003-08-02
PT1345896E (pt) 2009-02-19
NO20032758L (no) 2003-06-17
HRP20030607A2 (en) 2005-06-30
DE60137364D1 (de) 2009-02-26
CN1273449C (zh) 2006-09-06
US20040220255A1 (en) 2004-11-04
MXPA03005879A (es) 2003-09-10
US20030114686A1 (en) 2003-06-19
HUP0302519A3 (en) 2008-10-28
CA2626317A1 (en) 2002-07-04
EP2000461A1 (en) 2008-12-10
CA2431068C (en) 2008-06-10
KR100790766B1 (ko) 2008-01-03
JP2009221216A (ja) 2009-10-01
HUP0302519A2 (hu) 2003-12-29
ZA200304297B (en) 2004-08-16
PL365312A1 (en) 2004-12-27
CA2622727A1 (en) 2002-07-04
US7538136B2 (en) 2009-05-26
ES2319870T3 (es) 2009-05-14
US20090281162A1 (en) 2009-11-12
NZ527048A (en) 2004-12-24
CA2622697A1 (en) 2002-07-04
CA2431068A1 (en) 2002-07-04
WO2002051804A1 (en) 2002-07-04
EP1345896B1 (en) 2009-01-07
SK9532003A3 (en) 2004-04-06
ATE420070T1 (de) 2009-01-15
CZ20032019A3 (cs) 2003-10-15
CA2622477A1 (en) 2002-07-04
CA2623599A1 (en) 2002-07-04
CN1483022A (zh) 2004-03-17
JP2004516311A (ja) 2004-06-03
EP1345896A1 (en) 2003-09-24
IL156280A0 (en) 2004-01-04

Similar Documents

Publication Publication Date Title
NO20032758L (no) Krystallinske former av Atorvastatin
DE69915004D1 (de) 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
ZA200309887B (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
SI1535613T1 (sl) Postopek za pripravo polimorfne oblike atorvastatin kalcija
CA2416867A1 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
ATE272398T1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
DE60226044D1 (de) Kristalline formen von fluvastatin-natrium
EA200000431A2 (ru) Новые замещенные димерные соединения, способ их получения и фармацевтические композиции, содержащие их
EA200300579A1 (ru) Соединение лактама
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
CA2508871A1 (en) Crystalline form f of atorvastatin hemi-calcium salt
NO20016151L (no) Fremstilling av substituerte piperidin-4-oner
PT1206452E (pt) Processo de preparacao de compostos benzoper-hidroisoindole
MY129094A (en) Condensed polycyclic compounds
ES2185599T3 (es) Preparacion de intermediarios de la imidazodiacepina.
EA200300400A1 (ru) 17α-ФТОРАЛКИЛСТЕРОИДЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ЭТИ СОЕДИНЕНИЯ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
HUP0401895A2 (hu) Paroxetin N-formil származékai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE60213541D1 (de) Discodermolid-Analoga und ihre pharmazeutische Verwendung
BR0112849A (pt) Processo para a preparação de um composto quiral, e, composto quiral
NO20032707L (no) Ny fremgangsmåte for fremstilling av diaryl-4- aminopiperidinylforbindelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application